Nanobiotix Stock Forum

$Nanobiotix(NBTX.US)$
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, whe...

$Nanobiotix(NBTX.US)$
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announced new data from Study 1100, showing disease control and tumor response in patients treated with RT-activated NBTXR3 followed by anti-PD-1 therapy for second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The stud...

$Nanobiotix(NBTX.US)$
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) has announced the presentation of new data from its US Phase 1 Study 1100 at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO). The study evaluates NBTXR3 combined with anti-PD-1 therapy in patients with recurre...

$Nanobiotix(NBTX.US)$
NEWS
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix has announced significant progress in its global collaboration with Janssen to develop and commercialize its radioenhancer NBTXR3. This collaboration aims to expand the application of NBTXR3 in treating cancer patients who undergo radiotherapy. Key updates include the removal of a planned futility analysis for the ongoing Phas...

$Nanobiotix(NBTX.US)$ Good job done